Trevi Therapeutics (TRVI) Interest Expenses (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Interest Expenses of $210000.0 for Q1 2026, up 29.63% year-over-year from $162000.0 in Q1 2025, and up 180.77% quarter-over-quarter from -$260000.0 in Q4 2025.
Trevi Therapeutics (TRVI) Interest Expenses (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Interest Expenses history runs 9 years deep, the most recent figure standing at $210000.0 for Q1 2026.
- In Q1 2026, Interest Expenses rose 29.63% year-over-year to $210000.0; the TTM figure through Mar 2026 stood at $210000.0 (up 29.63% YoY), while the FY2025 annual figure was $82.7 million, up 608.91% from the prior year.
- Interest Expenses for Q1 2026 stood at $210000.0, up from -$260000.0 in the prior quarter.
- The five-year high for Interest Expenses was $1.4 million in Q1 2024, with the low at -$260000.0 in Q4 2025.
- The 5-year median for Interest Expenses is $231000.0 (2023), against an average of $402764.7.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses surged 779.08% in 2024, then slumped 26100.0% in 2025.
- Trevi Therapeutics' Interest Expenses stood at $499000.0 in 2022, then tumbled by 111.22% to -$56000.0 in 2023, then surged by 101.79% to $1000.0 in 2024, then plunged by 26100.0% to -$260000.0 in 2025, then surged by 180.77% to $210000.0 in 2026.
- Business Quant data shows TRVI's Interest Expenses at $210000.0 in Q1 2026, -$260000.0 in Q4 2025, and $937000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Trevi Therapeutics | 2.63 Bn | 2.63 Bn | - | 456,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 456,000.00 |
| Jun 30, 2026 | 456,000.00 |
| Mar 31, 2026 | 210,000.00 |
| Mar 31, 2026 | 210,000.00 |
| Dec 31, 2025 | -260,000.00 |
| Dec 31, 2025 | -260,000.00 |
| Sep 30, 2025 | 937,000.00 |
| Sep 30, 2025 | 937,000.00 |
| Jun 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 1.03 Mn |
| Mar 31, 2025 | 162,000.00 |
| Mar 31, 2025 | 162,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | 216,000.00 |
| Sep 30, 2024 | 216,000.00 |
| Jun 30, 2024 | 1.35 Mn |
| Jun 30, 2024 | 1.35 Mn |
| Mar 31, 2024 | 1.42 Mn |
| Mar 31, 2024 | 1.42 Mn |